Skip to main content

Day: July 19, 2021

Cosmetic Packaging Market worth USD 64.61 billion by 2027, registering a CAGR of 5.47% – Report by Market Research Future (MRFR)

New York, July 19, 2021 (GLOBE NEWSWIRE) — Cosmetic Packaging Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Cosmetic Packaging Market Research Report, Materials, Product, Application and Region – Forecast till 2027” the market worth USD 64.61 billion by 2027, registering a CAGR of 5.47% during the forecast period (2021 – 2027), The market was valued at USD 48.78 billion in 2020. The cosmetic packaging market outlook appears extremely positive. Increasing research and development activities and huge investments by packaging manufacturers are the latest cosmetic packaging market trends. Moreover, increasing consumer preference for high-quality products and changing lifestyles escalate the market on the global platform. With the increasing consumer focus on high-quality...

Continue reading

Guardian Capital Announces July 2021 Distributions for Guardian Capital ETFs

TORONTO, July 19, 2021 (GLOBE NEWSWIRE) — Guardian Capital LP announces the following regular cash distributions for the period ending July 31, 2021, in respect of the Guardian Capital ETFs listed below. In each case, the distribution will be paid on July 30, 2021 to unitholders of record on July 26, 2021. The ex-dividend date in each case is July 23, 2021.  Exchange Traded Fund Series of ETF Units DistributionFrequency TradingSymbol Distribution Amount(per ETF Unit)Guardian Directed Equity Path ETF Hedged Monthly GDEP $0.0685Guardian Directed Equity Path ETF Unhedged Monthly GDEP.B $0.0652Guardian Directed Premium Yield ETF Hedged Monthly GDPY $0.1076Guardian Directed Premium Yield ETF Unhedged Monthly GDPY.B $0.1024About Guardian Capital LPGuardian Capital LP is the manager and portfolio manager of the Guardian...

Continue reading

Brookfield Infrastructure Agrees with ISS’ Recommendation to Vote AGAINST the Pembina Transaction and Files Revised Offer to Purchase Inter Pipeline Ltd.

Brookfield Infrastructure agrees with the recommendation from leading independent proxy advisor, Institutional Shareholder Services (“ISS”), that Inter Pipeline Ltd. (“IPL”) Shareholders vote AGAINST IPL’s proposed transaction (the “Alternative Transaction”) with Pembina Pipeline Corporation (“Pembina”). Recommendation cites execution risk of the Alternative Transaction and a higher bid from Brookfield Infrastructure which offers financing certainty, no regulatory risk, and an all-cash option Brookfield Infrastructure’s Offer to purchase IPL for $21.23 per IPL common share1, on a prorated basis, represents a premium of C$1.53 or 8%2to the Alternative Transaction Shareholders may elect up to 100% cash consideration totalling C$20.00 per share of IPL without being subject to proration or 0.250 of a class A exchangeable subordinated voting...

Continue reading

Eve & Co. Announces Medical Cannabis Supply & Purchase Agreement With Cannamedical Pharma GmbH

STRATHROY, Ontario, July 19, 2021 (GLOBE NEWSWIRE) — Eve & Co Incorporated (“Eve & Co”, “we”, “us” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF), is pleased to announce that its wholly-owned subsidiary, Natural MedCo Ltd. (“NMC”) has successfully entered into a Medical Cannabis Supply and Purchase Agreement (the “Agreement”) with Cannamedical Pharma® GmbH (“CM”), an import / export and distribution company of para-pharmaceutical, medicinal and narcotic products headquartered in Cologne, Germany. Pursuant to the Agreement, NMC will export medical graded dried cannabis flower to CM and CM will distribute medical graded cannabis products in Germany. CM specializes in the import and distribution of medicinal cannabis to pharmacies and clinical facilities in the European Union (the “EU”). “We are very pleased to be able to...

Continue reading

Grom Social Enterprises to Present at the Emerging Growth Conference on Wednesday, July 21, 2021

BOCA RATON, FL, July 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Grom Social Enterprises, Inc. (NASDAQ: GROM) (“Grom”, the “Company”), a social media platform and original content provider for children under the age of 13, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, July 21, 2021  The next Emerging Growth Conference is presenting on Wednesday, July 21, 2021. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s CEO Darren Marks and Grom Social’s President, Paul Ward in real time.  Mr. Marks and Mr. Ward will perform a presentation and may subsequently open the floor for questions. Please ask your questions during the event and Mr. Marks and Mr. Ward will do their best to get...

Continue reading

Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors

Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of DirectorsPluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of DirectorsHAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the Tel Aviv University’s School of Public Health, and Mr. Doron Birger, a high-tech industry executive with a background in bringing groundbreaking products to market. Prof. Shalev has more than 30 years of experience working in clinical environments and research settings at the intersection of health and technology. She was the founder and Chief Executive Officer...

Continue reading

Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform

Exclusive Global Development and Commercialization Rights for Recombinant Human Collagen-Based Biosynthetic CorneaClinical Stage Asset Has Potential for First Approved Biosynthetic Human CorneaBiosynthetic Cornea Designed to Address Significant Unmet Need in Global Demand for Corneal Grafts for the Treatment of Corneal BlindnessEdward Holland, MD, Joins Eluminex’s Scientific Advisory BoardSUZHOU, China and SAN FRANCISCO, July 19, 2021 (GLOBE NEWSWIRE) — Eluminex Biosciences (Suzhou) Limited (Eluminex), an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a US-subsidiary office in San Francisco Bay Area, California, announced today that it has exclusively licensed global rights for the development and commercialization of an investigational biosynthetic cornea derived from recombinant human...

Continue reading

REGO Payment Architectures, Inc. Announces Upcoming Release of Mazoola(SM) version 3.0 and its unique “Super App” Capabilities

Because your child’s privacy matters The Children’s Online Privacy Protection Act (“COPPA”) and the General Data Protection Regulation (“GDPR”) compliance drive world-class privacy and consent policy features BLUE BELL, Pa., July 19, 2021 (GLOBE NEWSWIRE) — REGO Payment Architectures, Inc. (“REGO”) (OTCQB:RPMT) today announced the upcoming launch of its MazoolaSM version 3.0, a digital-wallet platform that allows children to fully participate in the digital economy in a secure and protected manner. The super app is scheduled to be released August 9th and expected to quickly become a perennial leader in the family neobanking, digital wallet space. As the only certified COPPA and GDPR compliant super app and with mounting pressure to protect children’s identity, MazoolaSM is uniquely positioned to address the 70M+ Gen Z Kids and...

Continue reading

Sigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development

CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development. Most recently, Mr. Rai served as Vice President, Corporate Development, Strategy & Alliance Management at Frequency Therapeutics where he was responsible for evolving the company’s overall business and corporate strategy and played an integral role in executing several financing rounds, including an Initial Public Offering. “We are pleased to welcome Ajay to our team, as he brings over two decades of business development, finance and partnering experience in the life sciences,” said Rogerio...

Continue reading

Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2021 financial results prior to market open on Thursday, July 29, 2021. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results. The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) passcode 2919379. Archived webcasts will be available on Intercept’s website for approximately two weeks. About Intercept Intercept is a biopharmaceutical company...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.